Shire Executive Committee
Flemming Ornskov, MD
Chief Executive Officer
Flemming assumed the position of Chief Executive Officer on April 30, 2013 and has been a member of the Board since January 2, 2013. He is also a member of the Company’s Executive Committee.
Flemming brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG, and of Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. Prior to this, from 2008 to 2010, Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc.. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming had roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.
Chief Financial Officer
Jeffrey "Jeff" joined Shire in 2003 and is Shire’s Chief Financial Officer. He is also a member of Shire’s Executive Committee and was appointed to the Board of Directors on April 30, 2015.
Jeff has held leadership positions in finance supporting the Neuroscience, Gastrointestinal and Rare Diseases business units as well as the positions of Interim Chief Financial Officer and Head of Investor Relations. In addition, Jeff oversaw the operations of the Rare Diseases business unit in North America, Latin America and Asia Pacific, as well as leading the integration of the legacy-Viropharma rare disease products into the Shire portfolio. Prior to joining Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of corporate finance and business development roles, in addition to serving as a commissioned officer in the U.S. Navy. He received a Bachelor of Arts in Economics from Duke University and a Master of Business Administration in Finance from the Kelly School of Business at Indiana University.
Interim General Counsel and Head of Corporate Development
Mark has been with Shire since 2013. He inititally led the Internal Medicine Business Unit and is now Interim General Counsel. He is also Shire’s Head of Corporate Development leading the Business Development, Planning and Program Management, and Strategy functions. He is also a member of Shire’s Executive Committee.
Prior to joining Shire Mark was Chief Executive Officer at Proteostasis Therapeutics, Inc.. He also held positions with Genzyme Corporation and practiced law at the firm Palmer & Dodge.
Head of Research and Development
Philip “Phil” has been with Shire since 2010. He led Research and Development within the Rare Diseases Business Unit and is now Shire’s Head of Research and Development. He is also a member of Shire’s Executive Committee.
Phil was previously Chief Scientific Officer and President at Resolvyx Pharmaceuticals, Inc., prior to which he worked for Boehringer Ingelheim Pharmaceuticals, Inc.. He also held positions at Pfizer, Inc. and Merck & Co., Inc..
Chief Human Resources Officer
Ginger joined Shire in 2014 and is Shire’s Chief Human Resources Officer. She is also a member of Shire’s Executive Committee.
Ginger was previously Head of Human Resources at Dunkin’ Brands Group, Inc. prior to which she held roles at Bristol-Myers Squibb Company, Novo Nordisk A/S and Novartis AG.
Our global reach
Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.